Literature DB >> 3621160

Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.

P A de Bruin, G Griffioen, H W Verspaget, J H Verheijen, C B Lamers.   

Abstract

Malignant changes are often accompanied by alterations in activity and composition of the plasminogen activators (PA). To study the relationship between PA expression and the development of colorectal cancer, we determined urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) activity in normal mucosa (n = 80), adenomatous polyps (n = 76), and adenocarcinomas (n = 71) of the colon. Tissues obtained from surgical resection or polypectomy were analyzed for t-PA and u-PA activity in a specific enzymatic assay using plasminogen, a chromogenic substrate, and selective quenching with monospecific antibodies to both activators. The plasminogen activator activities were found to be changed in adenocarcinomas as compared to normal mucosa. The relative contribution of u-PA (expressed as percentage of u-PA) was raised from 6 to 50% for, respectively, normal mucosa and adenocarcinoma. This change could be attributed to a 3-fold decrease in t-PA activity and a 5-fold increase in u-PA activity in the carcinomas. Adenomatous polyps as a group showed percentages of u-PA [20.2 +/- 1.3 (SE)] which were intermediate as well as significantly different (P less than 0.001) from those of normal mucosa and adenocarcinomas. This observation was strengthened by a gradual rise in the relative contribution of u-PA in four resection specimens containing both adenomatous polyps and adenocarcinomas. Zymography showed the presence of minor quantities of PA-PA inhibitor complexes in the tissue extracts studied. The present study shows that the sequence of normal mucosa-adenomatous polyp-adenocarcinoma in the colon is associated with a parallel change in plasminogen activator activity. Thus, change in the regulation of plasminogen activator activity is an early event in the development of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621160

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 2.  GATA factors in gastrointestinal malignancy.

Authors:  Funmi Ayanbule; Narasimhaswamy S Belaguli; David H Berger
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

3.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

Authors:  J Grøndahl-Hansen; E Ralfkiaer; L T Kirkeby; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

4.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

5.  Cell associated urokinase activity and colonic epithelial cells in health and disease.

Authors:  P R Gibson; E van de Pol; W F Doe
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 6.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 7.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

8.  Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies.

Authors:  Zuoan Yi; Ramiro Diz; Aaron J Martin; Yves Maurice Morillon; Douglas E Kline; Li Li; Bo Wang; Roland Tisch
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

9.  Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.

Authors:  S Ganesh; C F Sier; M M Heerding; J H van Krieken; G Griffioen; K Welvaart; C J van de Velde; J H Verheijen; C B Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.

Authors:  Y H Kook; J Adamski; A Zelent; L Ossowski
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.